Crossmark

Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma

Crossref DOI link: https://doi.org/10.1038/s41598-019-47216-2

Published Online: 2019-07-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Enooku, Kenichiro

Nakagawa, Hayato

Fujiwara, Naoto https://orcid.org/0000-0002-4109-3421
Kondo, Mayuko

Minami, Tatsuya

Hoshida, Yujin https://orcid.org/0000-0001-9430-1426
Shibahara, Junji

Tateishi, Ryosuke https://orcid.org/0000-0003-3021-2517
Koike, Kazuhiko
Funding

Funding for this research was provided by:

Japan Agency for Medical Research and Development (JP18fk0210040)

Japan Agency for Medical Research and Development (JP18fk0210040)

MEXT | Japan Society for the Promotion of Science (18H02789)

Uehara Memorial Foundation

Daiichi Sankyo Foundation of Life Science

Takeda Science Foundation

Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care

Naito Foundation

Kobayashi Foundation for Cancer Research

Bristol-Myers Squibb Research Grant, SGH Foundation, MSD Life Science Foundation
License Information

Text and Data Mining valid from 2019-07-23

Version of Record valid from 2019-07-23
More Information

Article History

Received: 7 May 2019

Accepted: 12 July 2019

First Online: 23 July 2019

Competing Interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below